Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Johnson & Johnson : Doctors blame media for scaring patients off vaginal mesh implants

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 07:14pm CEST

Inaccurate media reporting about vaginal mesh implants and the lawsuits associated with them has caused patients to become fearful of mesh procedures that may be essential to improving their health, New Zealand general surgeon Dr Steven Kelly says.

In a piece published in the New Zealand Medical Journal on Friday, Kelly said the media “have over previous years done great harm to the reputation of mesh abdominal wall and groin hernia repair”.

Concerns have been escalating after thousands of women around the world reported chronic pain, mesh cutting through tissue and being left unable to walk or have sex after having mesh surgery to repair urinary incontinence and prolapse – conditions often caused by childbirth.

Related: What does pelvic mesh do and why are women suing over it? – explainer

US pharmaceutical company Johnson & Johnson, a major manufacturer of mesh implants, is fighting class actions in Australia and the US, and could face legal proceedings in the UK.

But the media had “published multiple articles claiming that mesh is unsafe and unproven”, Kelly said. “That is simply not true,” he wrote. “Patients whom require abdominal wall hernia repair are now fearful of mesh. New Zealand general surgeons are well trained in modern hernia surgery and the management of complications.”

Most short-term clinical trials have found high efficacy and low complication rates for the most common mesh implants used to treat incontinence and hernias. But there is a growing body of evidence that efficacy is lower and complication rates are higher when the mesh, also known as transvaginal mesh, is used to treat pelvic organ prolapse.

“It is very important for the public to understand that transvaginal mesh repair has a different risk profile compared to abdominal wall mesh repair [to treat hernia],” Kelly wrote.

“Transvaginal mesh is placed into the vaginal wall in an attempt to treat pelvic organ prolapse. It was initially presumed to be as safe as abdominal wall hernia mesh repair. However, over time there were increasing reports of significant problems with this mesh technique, including mesh erosion, chronic pain, mesh infection and dyspareunia [painful intercourse].”

While many of the problematic meshes have been removed from the market, controversy remains among experts about the risk profile of contemporary meshes and how they should be utilised to treat prolapse. But Kelly said it was essential to also reassure people that the complication rate for abdominal wall hernia repair using mesh was low.

The president of the Australian Medical Association, Dr Michael Gannon, said even in the case of mesh used to treat prolapse, “a minority of women having these kinds of operations have been damaged”.

“One in eight women who have delivered vaginally will need an operation for either prolapse or incontinence, and using surgical tape or mesh may be a part of their legitimate care,” Gannon said.

Related: 'Scandal' of vaginal mesh removal rates revealed by NHS records

“We seem to have forgotten how many women have been helped by these operations over the journey in acknowledging that some may have been harmed by it.”

Gannon, who is an obstetrician, said he had been involved in the treatment of women who had been harmed by the meshes. Like Kelly, he said the media had been guilty of misrepresenting the scale of the problem.

“I have a lot of sympathy for the minority of women injured by gynaecological mesh operations; they have chronic pain and a lot of cases are very hard to fix,” he said.

“Stories like theirs are highly charged, emotional stories that make for good copy and its inevitable the media would report them. It’s less interesting to talk to a woman who had an operation five years ago and their lives have been made a whole lot better.”

More than 100,000 transvaginal mesh lawsuits have been filed in the US, while more than 700 women comprise the Australian class action. NHS records have revealed that thousands of women have undergone surgery to have vaginal mesh implants removed during the past decade in the UK due to traumatic complications linked to the devices.

The CEO of the Health Issues Centre in Australia, Danny Vadasz, said pointing out that the majority of women to undergo mesh procedures had not been harmed was an attempt to deflect attention away from the medical profession.

He used the example of the drug Thalidomide, prescribed to women to treat insomnia and morning sickness and which was subsequently found to have caused severe deformities in babies born to women on the drug.

“No one said, ‘Oh yes, but hundreds of thousands of women got a good night’s sleep on the drug, and that outweighs the harm’,” Vadasz said.

Related: Vaginal mesh lawsuit: executive denies prioritising Johnson & Johnson interests

Vadasz said while it may be the case that complication rates were much lower among those who had mesh procedures to treat hernia, “patronising” comments from doctors were not helpful.

“Doctors need to stop taking this patronising ‘we are the experts why aren’t you listening to us’ approach,” he said.

“My frustration is that I’m on various reference groups and government committees dealing with the mesh issue and this narrative of ‘we made mistakes in the past and its fine now’ keeps emerging. But it’s not fine.

“To me it’s a part of this larger, poor attitude towards women and not listening to women when they say something is wrong, and not explaining the risks to them so they can give informed consent to procedures.”

Copyright © 2017 theguardian.com. All rights reserved., source Guardian Online

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
07/20JOHNSON & JOHNSON : Zach attack tames cold and wet Carnoustie
AQ
07/20JOHNSON & JOHNSO : johnson, & johnson
PU
07/20JOHNSON & JOHNSON : Janssen Pharmaceutical - Phase 3 CREDENCE Renal Outcomes Tri..
AQ
07/20JOHNSON & JOHNSON : Announces Quarterly Dividend for Third Quarter 2018
AQ
07/20Eversight Expands Offer Innovation Suite to Address $760 Billion Consumer Pac..
AQ
07/20JOHNSON & JOHNSON : BioCentury - Provention raises $64M IPO
AQ
07/20JOHNSON & JOHNSON : and Reports 2018 Second-Quarter Results
AQ
07/20JOHNSON & JOHNSON : Bayer - Phil Sharp to join Bayer UK and Ireland
AQ
07/20GENMAB : Announces Net Sales of DARZALEX for Second Quarter of 2018
AQ
07/20JOHNSON & JOHNSON : Janssen Announces U.S. FDA Approval of SYMTUZATM, the First ..
AQ
More news
News from SeekingAlpha
07/20FDA releases updated industry guidelines for development of generic abuse-det.. 
07/20YOUR DAILY PHARMA SCOOP : Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Posit.. 
07/20GERON : Anticipation Building 
07/19My Dividend Growth Portfolio - Q2 2018 Summary 
07/19Jane's June Dividend Increases And Income - Retirement Accounts 
Financials ($)
Sales 2018 81 273 M
EBIT 2018 24 895 M
Net income 2018 16 036 M
Debt 2018 12 563 M
Yield 2018 2,83%
P/E ratio 2018 18,33
P/E ratio 2019 16,48
EV / Sales 2018 4,37x
EV / Sales 2019 4,11x
Capitalization 343 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 143 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-8.53%342 779
PFIZER3.98%220 295
NOVARTIS-1.75%206 001
ROCHE HOLDING LTD.-5.90%203 399
MERCK AND COMPANY11.09%169 328
AMGEN10.27%127 577